Acucela Inc., a Kubota Pharmaceutical Group company, is committed to translating innovation into a diverse portfolio of drugs and devices to treat blinding eye diseases that affect tens of millions of people worldwide. The company's orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD). Acucela was founded by Dr. Ryo Kubota in 2002.